Jun Chung, PhD
Associate Professor, Department of Pathology
Basic Sciences Tower, Level 9
Stony Brook Medicine
Stony Brook, NY 11794-8691
Tel: (631) 469-7176
Fax: (631) 444-3424
Email: Jun.Chung@stonybrookmedicine.edu
Research Interests: Dr. Chung’s research is focused on development of therapeutics and diagnostics for breast cancers. Specific emphasis is on the molecular signature that makes Triple Negative Breast Cancers (TNBCs) aggressive so that TNBC specific biomarker and therapeutic intervention can be developed. Dr. Chung's laboratory has made substantive contributions in the area of integrin beta4 signaling in breast cancer invasion and metastasis. The current focus is on the development of targeted therapies in TNBC model by targeting integrin beta4 signaling and its downstream micro-RNAs. Dr. Chung's laboratory is particularly interested in characterizing tumor suppressing micro-RNAs whose expression is suppressed in metastatic breast cancers such as TNBCs. Current projects involve chemical modification of these tumor suppressing micro-RNAs to enhance their therapeutic efficacy and delivery. Multiple projects in these subjects are currently available for Ph.D. thesis and post-doctoral training.
Education:
| Institution and Location | Degree | Year | Field of Study |
| Yonsei University, Seoul, Korea | B.S. | 1991 | Biochemistry |
| University of Minnesota, Minneapolis, MN | M.S. | 1994 | Genetics and Cell Biology |
| Washington University School of Medicine, St. Louis, MO | Ph.D. | 1999 | Molecular Cell Biology |
Positions and Employment:
| 1994-1999 | Research Assistant, Molecular Cell Biology Program, Washington University School of Medicine, St. Louis, MO |
| 2000-2005 | Research Associate, Department of Pathology, Harvard Medical School, Boston, MA |
| 2005 | Postdoc, Department of Pathology, Harvard Medical School, Boston, MA |
| 2007-present | Consultant, Tumor Biology, Biogen IDEC, Inc., San Diego, CA |
| 2005-2013 | Member, Graduate Faculty (Biochemistry & Molecular Biology), Louisiana State University, Shreveport, LA |
| 2006-2013 | Member, Breast Cancer Focus Group, Louisiana State University Health Sciences Center, Shreveport, LA |
| 2005-2013 | Member, Invasion and Metastasis Group, Louisiana State University Health Sciences Center, Shreveport, LA |
| 2005-2013 | Member, Feist-Weiller Cancer Center, Louisiana State University Health Sciences Center, Shreveport, LA |
| 2005-2011 | Assistant Professor, Department of Biochemistry, Louisiana State University Health Sciences Center, Shreveport, LA |
| 2011-2013 | Associate Professor w/tenure, Dept. of Biochemistry, Louisiana State University Health Sciences Center, Shreveport, LA |
| 2012-2013 | Director of Breast Cancer Focus Group in Feist Weiler Cancer Center, Shreveport, LA |
| 2013-2015 | Oklahoma TSET Cancer Research Scholar, Stephen Cancer Center, University of Oklahoma Health Sciences Center |
| 2013-2015 | Associate Professor, Department of Physiology, University of Oklahoma Health Sciences Center |
| 2015-present | Associate Professor, Department of Pathology, Stony Brook Medicine |
Selected Publications (Representatives from 72 publications)
| Chung J, Gao AG, Frazier WA. Thrombospondin acts via integrin associated protein to activate the platelet integrin aIIbb3. J Biol Chem 1997;272:14740-46 |
| Chung J, Wang XQ, Lindberg FP, Frazier WA. Thrombospondin-1 acts via IAP/CD47 to synergize with collagen in a2b1-mediated platelet activation. Blood 1999;94:642-48 |
| Green JM, Zhelesnyak A, Chung J, Lindberg FP, Sarfati M, Frazier WA, Brown EJ. Role of Cholesterol in formation and function of a signaling complex involving avb3, integrin associated protein (CD47), and heterotrimeric G proteins. J Cell Biol 1999 146: 673-82 |
| Bachelder RE, Crago A, Chung J, Wendt M, Shaw L, Robinson G, and Mercurio AM. VEGF is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001, 61: 5736-40 |
| Chung J, Bachelder RE, Lipscomb E, Shaw LM, and Mercurio AM. Integrin (a6b4) regulation of eIF-4E activity and VEGF translation. J Cell Biol 2002, 158:165-174 |
| Mercurio AM, Bachelder RE, Bates, RC and Chung J. Autocrine Signaling in Carcinoma: VEGF and the a6b4 Integrin. Semin Cancer Biol 2004, 14: 115-122 |
| Chung J* and Mercurio AM. Contribution of the a6 Integrins to Breast Carcinoma Cell Survival and Progression. Mol Cells 2004, 17 (2): 203-209 |
| Chung J, Yoon S, Datta K, Bachelder RE and Mercurio AM. Hypoxia induced VEGF transcription and survival is dependent on a6 integrin expression in breast carcinoma cells. Cancer Res 2004, 64: 4711-4716 |
| Chung J, Yoon S, Lipscomb E and Mercurio AM. Met and the a6b4 integrin can function independently to promote carcinoma invasion. J Biol Chem 2004, 279: 32287-32293 |
| Lui L, Chen L, Chung J and Huang S. Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins. Oncogene 2008 May, 27:4998-5010 |
| Kim HI, Huang H, Cheepala S, Huang S and Chung J*. Curcumin inhibition of integrin (a6b4) dependent breast cancer cell motility and invasion. Cancer Prevention Research 2008, Oct, 1 (5):385-391 |
| Kim TH, Kim HI, Soung YH, Shaw LM and Chung J*.Integrin (a6b4) Signal through Src to increase a Metastasis Promoting Factor, S100A4 Expression: Implications to Cancer Cell Invasion. Molecular Cancer Research 2009, Oct 6 7(10) |
| Korneeva NL, Soung YH, Kim HI, Cheng B, Giordano A, Rhoads RE, Gram H, and Chung J*. Mnk kinase regulates integrin (a6b4) dependent translation initiation via alteration of eIF4F integrity Molecular Cancer Research 2010 Oct 21 Vol 8, Issue 12: 1571-1578 (selected as a highlighted article by editors) |
| Soung YH and Chung J*. Curcumin inhibition of functional interaction between integrin a6b4 and epidermal growth factor receptor. Molecular Cancer Therapeutics 2011 May;10(5):883-91 |
| Soung YH, Pruitt K, Chung J*. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Scientific Reports. 2014 Jan 24: 4:3846 |
| Chen L, Xu B, Liu L, Liu C, Luo Y, Chen X, Barzegar M, Chung J, and Huang S. Both mTORC1 and mTORC2 are involved in the regulation of cell adhesion. Oncotarget 2015 Jan 23: 1-15 |
| Soung YH, Coleman D, Cardelli JA, and Chung J*. Curcumin inhibits DHHC3 activity and palmitoylation of integrin beta4 in breast cancer cells. Plos One 2015 May 4: 10 (5): e0125399 |
| Soung YH, Nguyen T, Cao H, Lee J and Chung J*. Emerging roles of exosomes in cancer invasion and metastasis. BMB Reports 2015 Nov 20 (Epub ahead of print) |
Soung YH, Nguyen T, Cao H, Lee J and Chung J*. Emerging roles of exosomes in cancer invasion and metastasis. BMB Reports 2016 Jan, 49 (1): 18-25
Soung YH, Ford S, Zhang V, and Chung J*. Exosomes in cancer diagnostics. Cancers (Basel). 2017 Jan 12:9 (1)
Soung YH, Kashahp T, Ngyuen T, Yadav G, Chang H, Landesman Y, and Chung J*. Selective inhibitor of nuclear export (SINE) compounds block migration and proliferation of Triple Negative Breast Cancer cells by restoring expression of ARRDC3. Oncotarget. 2017 May 18;8(32):52935-52947.
Soung YH, Ford S, Zhang C, and Chung J*. The role of ARRDC3 in regulating endocytic recycling and extracellular vesicle sorting of integrin beta4 in breast cancer. Cancers (Basel). 2018 Dec 11;10(12).
Soung YH, H Chung, C Yan, J Ju, and Chung J*. Arrestin domain containing 3 reverses epithelial to mesenchymal transition and chemo-resistance of TNBC cells by up-regulating expression of miR-200b. Cells 2019. July 10; 8 (7).
Soung YH, Chung HS, Fesler A, Kim H, Oh ES Ju J, and Chung J*. Therapeutic potentials of modified miR-489 mimic in Triple Negative Breast Cancer. Cancers 2020. Aug 7;12(8):2209.
*Corresponding author
